1
|
Niemann G, Germer M, Hauf M, Poelsler G, Röder J, Schüttrumpf J. Hyperimmunplasma: Gewinnung, Verarbeitung und therapeutische
Anwendungen. TRANSFUSIONSMEDIZIN 2023. [DOI: 10.1055/a-1894-1146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
ZusammenfassungDas Prinzip der passiven Immunisierung ist seit dem 19. Jahrhundert bekannt und
wird auch bei aktuellen Pandemien als Ansatz zur Prophylaxe und Therapie
eingesetzt. Der Schutz wird hierbei übertragen durch Blut, Serum oder
Plasma, welche Immunglobuline gegen spezifische Krankheitserreger,
Bakterientoxine oder sonstige Antigene enthalten, sowie durch aus Humanplasma
industriell aufgereinigte Immunglobuline. Die aktuell verwendeten
Reinigungsverfahren für Immunglobuline aus Humanplasma beruhen auf der
von Edwin J. Cohn entwickelten Fraktionierung von Plasma. Zur Gewinnung von
Immunglobulinen mit hohen Antikörpertitern gegen spezifische Antigene,
sogenannte Hyperimmunglobuline, muss zunächst Hyperimmunplasma gezielt
von ausgewählten Spendern gewonnen werden. Diese Spender haben
erhöhte Antikörpertiter gegen spezifische Krankheitserreger,
Bakterientoxine oder sonstige Antigene, wenn sie im Rahmen einer vorangegangenen
Infektion natürlich immunisiert wurden, einen zugelassenen Impfstoff zur
Immunisierung erhalten haben oder gezielt zum Zweck der Plasmaspende immunisiert
wurden. Aktuell sind in Deutschland, Österreich und der Schweiz
Hyperimmunglobulinprodukte für verschiedene Anwendungen im Patienten
zugelassen, von denen die meisten aus humanem Blutplasma gewonnen werden. Um die
Herstellung der Produkte und damit letztlich die Behandlung der Patienten
gewährleisten zu können, werden resiliente Lieferketten
benötigt. Hierzu bedarf es unter anderem Änderungen in den
Rahmenbedingungen für die Spenderimmunisierung in Deutschland.
Collapse
|
2
|
Miller D, Vanderlee G, Vaute O, Krause M. PlasmaCap EBA: An innovative method of isolating plasma proteins from human plasma. Vox Sang 2023; 118:128-137. [PMID: 36454586 DOI: 10.1111/vox.13388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2022] [Revised: 11/10/2022] [Accepted: 11/21/2022] [Indexed: 12/05/2022]
Abstract
BACKGROUND AND OBJECTIVES The growing demand for immunoglobulin (IG) requires development of improved plasma fractionation methods to provide higher yields in a cost effective, scalable manner without compromising product purity and efficacy. A novel protein extraction method, utilizing expanded bed adsorption (EBA) chromatography, has been developed. PlasmaCap IG (10% liquid formulation intravenous IG [IVIG]) is the first plasma-derived product manufactured using PlasmaCap EBA technology. MATERIALS AND METHODS The PlasmaCap EBA platform consists of a series of consecutive columns which bind a target protein, or group of proteins, in their native state directly from cryo-poor plasma. EBA chromatography includes five key steps: (1) expand, (2) sanitize and equilibrate, (3) load, (4) wash and (5) elute. These steps are made possible using high-density tungsten-carbide agarose beads, suspended by upward flow. The PlasmaCap EBA process was evaluated during Evolve's clinical campaign for scalability, product quality and yield. RESULTS PlasmaCap EBA technology can be predictably scaled by maintaining the minimum residence time and residence time distribution for EBA columns of different diameters. Scalability of the manufacturing process was demonstrated by the 50-fold volumetric increase from laboratory-scale lots to clinical-scale lots. The process is also associated with enhanced product purity, such as lower aggregates. The PlasmaCap EBA process is expected to have the same or better yield and purity at commercial scale production compared to the clinical campaign. CONCLUSION The PlasmaCap EBA platform was used to successfully develop PlasmaCap IG (10% liquid formulation IVIG) with proven scalability, product quality and yield.
Collapse
Affiliation(s)
- David Miller
- Evolve Biologics, Inc., Mississauga, Ontario, Canada
| | | | - Olivier Vaute
- Evolve Biologics, Inc., Mississauga, Ontario, Canada
| | - Mark Krause
- Evolve Biologics, Inc., Mississauga, Ontario, Canada
| |
Collapse
|
3
|
Raoufinia R, Balkani S, Keyhanvar N, Mahdavipor B, Abdolalizadeh J. Human albumin purification: a modified and concise method. J Immunoassay Immunochem 2018; 39:687-695. [DOI: 10.1080/15321819.2018.1531884] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Ramin Raoufinia
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Cellular and Molecular Research Center, School of medicine, Sabzevar University of medical sciences, Sabzevar, Iran
| | - Sanaz Balkani
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Neda Keyhanvar
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Behroz Mahdavipor
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Jalal Abdolalizadeh
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Paramedical faculty, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
4
|
van Dijk A, Hedegaard CJ, Haagsman HP, Heegaard PMH. The potential for immunoglobulins and host defense peptides (HDPs) to reduce the use of antibiotics in animal production. Vet Res 2018; 49:68. [PMID: 30060758 PMCID: PMC6066942 DOI: 10.1186/s13567-018-0558-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Accepted: 06/28/2018] [Indexed: 02/08/2023] Open
Abstract
Innate defense mechanisms are aimed at quickly containing and removing infectious microorganisms and involve local stromal and immune cell activation, neutrophil recruitment and activation and the induction of host defense peptides (defensins and cathelicidins), acute phase proteins and complement activation. As an alternative to antibiotics, innate immune mechanisms are highly relevant as they offer rapid general ways to, at least partially, protect against infections and enable the build-up of a sufficient adaptive immune response. This review describes two classes of promising alternatives to antibiotics based on components of the innate host defense. First we describe immunoglobulins applied to mimic the way in which they work in the newborn as locally acting broadly active defense molecules enforcing innate immunity barriers. Secondly, the potential of host defense peptides with different modes of action, used directly, induced in situ or used as vaccine adjuvants is described.
Collapse
Affiliation(s)
- Albert van Dijk
- Division Molecular Host Defence, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Chris J. Hedegaard
- Innate Immunology Group, National Veterinary Institute, Technical University of Denmark, Kongens Lyngby, Denmark
| | - Henk P. Haagsman
- Division Molecular Host Defence, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Peter M. H. Heegaard
- Innate Immunology Group, National Veterinary Institute, Technical University of Denmark, Kongens Lyngby, Denmark
| |
Collapse
|
5
|
Gomes CSG, Fashina A, Fernández‐Castané A, Overton TW, Hobley TJ, Theodosiou E, Thomas ORT. Magnetic hydrophobic-charge induction adsorbents for the recovery of immunoglobulins from antiserum feedstocks by high-gradient magnetic fishing. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY (OXFORD, OXFORDSHIRE : 1986) 2018; 93:1901-1915. [PMID: 30008504 PMCID: PMC6032826 DOI: 10.1002/jctb.5599] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2017] [Revised: 01/26/2018] [Accepted: 01/26/2018] [Indexed: 05/07/2023]
Abstract
BACKGROUND The extraction of biopharmaceuticals from plasma and serum often employs overly complicated antiquated procedures that can inflict serious damage on especially prone protein targets and which afford low purification power and overall yields. This paper describes systematic development of a high-gradient magnetic fishing process for recovery of immunoglobulins from unclarified antiserum. RESULTS Non-porous superparamagnetic particles were transformed into hydrophobic-charge induction adsorbents and then used to recover immunoglobulins from rabbit antiserum feedstocks. Comprehensive characterisation tests conducted with variously diluted clarified antiserum on a magnetic rack revealed that immunoglobulin binding was rapid (equilibrium reached in <45 s), strong (Kd < 0.1 mg mL-1), of high capacity (Qmax = 214 mg g-1), and pH and ionic strength dependent. In a high-gradient magnetic fishing process conducted with the same adsorbent, and a conventional 'magnetic filter + recycle loop' arrangement, >72% of the immunoglobulin present in an unclarified antiserum feed was recovered in 0.5 h in >3-fold purified form. CONCLUSIONS Fast magnetic particle based capture of antibodies from an unclarified high-titre feed has been demonstrated. Efficient product recovery from ultra-high titre bioprocess liquors by high-gradient magnetic fishing requires that improved magnetic adsorbents displaying high selectivity, ultra-high capacity and operational robustness are used with 'state-of-the-art' rotor-stator magnetic separators. © 2018 The Authors. Journal of Chemical Technology & Biotechnology published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Collapse
Affiliation(s)
- Cláudia SG Gomes
- Institute of Biotechnology and BiomedicineTechnical University of DenmarkLyngbyDenmark
| | - Adedayo Fashina
- School of Chemical EngineeringUniversity of BirminghamBirminghamUK
| | | | | | - Timothy J Hobley
- National Food InstituteTechnical University of DenmarkLyngbyDenmark
| | | | - Owen RT Thomas
- School of Chemical EngineeringUniversity of BirminghamBirminghamUK
| |
Collapse
|
6
|
Mousavi Hosseini K, Ghasemzadeh M. Implementation of Plasma Fractionation in Biological Medicines Production. IRANIAN JOURNAL OF BIOTECHNOLOGY 2017; 14:213-220. [PMID: 28959338 PMCID: PMC5434990 DOI: 10.15171/ijb.1401] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Context
The major motivation for the preparation of the plasma derived biological medicine was the treatment of casualties from the Second World War. Due to the high expenses for preparation of plasma derived products, achievement of self-sufficiency in human plasma biotechnological industry is an important goal for developing countries.
Evidence Acquisition
The complexity of the blood plasma was first revealed by the Nobel Prize laureate, Arne Tiselius and Theodor Svedberg, which resulted in the identification of thousands of plasma proteins. Among all these proteins, four of which are commercially important for production due to significant need of patients. These four products are: albumin, IgG, factor VIII, and Factor IX. The starting material for the production of biological drugs from plasma is natural which is different from synthetic starting material. So, the quality of plasma as starting material plays an important role in the quality of final product. Introducing new techniques for preparation of the biological drugs from human plasma has resulted in the improvements in purity of products, higher safety, and yield noticeably. Still, the backbone of the modern plasma fractionation technique is mainly based on cold ethanol fractionation of the human plasma that is almost the same as fractionation of crude oil, breaking it down into its components. The demand for IgG for treating immune deficiencies and coagulation factor VIII for hemophilia A determines how to design the plasma fractionation industry in terms of capacity. Nowadays, cold ethanol fractionation has followed by chromatographic methods, since they offer higher purity. In this review, we describe different methods of plasma fractionation such as cold ethanol fractionation, gel filtration, fractionation by salt, and fractionation by polyethylene glycol. There is no doubt that the four main products of human plasma are albumin, IgG, coagulation factor VIII, and IX, which their methods of separation from human plasma have been explained in this paper.
Conclusions
It can be concluded that plasma fractionation with ethanol at low temperature for the preparation of the main human plasma biological components including albumin, IgG, coagulation factors VIII, and IX is still the most widely used method at an industrial scale. Nowadays, this method is being used in combination with different chromatographic techniques in order to achieve a higher quality and the yield.
Collapse
Affiliation(s)
- Kamran Mousavi Hosseini
- Biotechnology Department, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
| | - Mehran Ghasemzadeh
- Biotechnology Department, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
| |
Collapse
|
7
|
D'Souza RN, Kakarla PB, Yelemane V, Meyer R, den Boer P, Fernández-Lahore M. Controlling cell adhesion in antibody purification by expanded bed adsorption chromatography. Sep Purif Technol 2017. [DOI: 10.1016/j.seppur.2017.03.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
8
|
Raoufinia R, Mota A, Keyhanvar N, Safari F, Shamekhi S, Abdolalizadeh J. Overview of Albumin and Its Purification Methods. Adv Pharm Bull 2016; 6:495-507. [PMID: 28101456 PMCID: PMC5241407 DOI: 10.15171/apb.2016.063] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Revised: 09/08/2016] [Accepted: 09/10/2016] [Indexed: 01/06/2023] Open
Abstract
As the most frequent plasma protein, albumin constitutes more than 50% of the serum proteins in healthy individuals. It has a key role in oncotic pressure maintenance and it is known as a versatile protein carrier for transportation of various endogenous and exogenous ligands. Reduced amounts of albumin in the body will lead to different kinds of diseases such as hypovolemia and hypoproteinemia. It also has various indications in shocks, burns, cardiopulmonary bypass, acute liver failure and etc. Further applications in research consist of cell culture supplement, drug delivery carrier and protein/drug stabilizer. So, the demand for albumin increased annually worldwide. Due to different applications of albumin, many efforts have been accomplished to achieve albumin during a long period of time. In this review, an overview of serum albumin and different purification methods are summarized.
Collapse
Affiliation(s)
- Ramin Raoufinia
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ali Mota
- Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Neda Keyhanvar
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Fatemeh Safari
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Sara Shamekhi
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Jalal Abdolalizadeh
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
- Paramedical faculty, Tabriz University of Medical Sciences, Tabriz, Iran
| |
Collapse
|
9
|
Burnouf T. Current status and new developments in the production of plasma derivatives. ACTA ACUST UNITED AC 2016. [DOI: 10.1111/voxs.12269] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- T. Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering; College of Biomedical Engineering; Taipei Medical University; Taipei Taiwan
| |
Collapse
|
10
|
Hedegaard CJ, Heegaard PMH. Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems. Vet Immunol Immunopathol 2016; 174:50-63. [PMID: 27185263 PMCID: PMC7127230 DOI: 10.1016/j.vetimm.2016.04.007] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Revised: 04/11/2016] [Accepted: 04/13/2016] [Indexed: 12/19/2022]
Abstract
Immunisation by administration of antibodies (immunoglobulins) has been known for more than one hundred years as a very efficient means of obtaining immediate, short-lived protection against infection and/or against the disease-causing effects of toxins from microbial pathogens and from other sources. Thus, due to its rapid action, passive immunisation is often used to treat disease caused by infection and/or toxin exposure. However immunoglobulins may also be administered prior to exposure to infection and/or toxin, although they will not provide long-lasting protection as is seen with active immunisation (vaccination) in which an immunological memory is established by controlled exposure of the host to the pathogen in question. With multi-factorial infectious diseases in production animals, especially those that have proven hard to control by vaccination, the potential of passive immunisation remains big. This review highlights a number of examples on the use of passive immunisation for the control of infectious disease in the modern production of a range of animals, including pigs, cattle, sheep, goat, poultry and fish. Special emphasis is given on the enablement of passive immunisation strategies in these production systems through low cost and ease of use as well as on the sources, composition and purity of immunoglobulin preparations used and their benefits as compared to current measures, including vaccination (also comprising maternal vaccination), antibiotics and feed additives such as spray-dried plasma. It is concluded that provided highly efficient, relatively low-price immunoglobulin products are available, passive immunisation has a clear role in the modern animal production sector as a means of controlling infectious diseases, importantly with a very low risk of causing development of bacterial resistance, thus constituting a real and widely applicable alternative to antibiotics.
Collapse
Affiliation(s)
- Chris J Hedegaard
- National Veterinary Institute, Technical University of Denmark, Section for Immunology and Vaccinology, The innate immunology Group, Denmark.
| | - Peter M H Heegaard
- National Veterinary Institute, Technical University of Denmark, Section for Immunology and Vaccinology, The innate immunology Group, Denmark
| |
Collapse
|
11
|
Natural Pig Plasma Immunoglobulins Have Anti-Bacterial Effects: Potential for Use as Feed Supplement for Treatment of Intestinal Infections in Pigs. PLoS One 2016; 11:e0147373. [PMID: 26824607 PMCID: PMC4744083 DOI: 10.1371/journal.pone.0147373] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 12/15/2015] [Indexed: 12/22/2022] Open
Abstract
There is an increasing demand for non-antibiotics solutions to control infectious disease in intensive pig production. Here, one such alternative, namely pig antibodies purified from slaughterhouse blood was investigated in order to elucidate its potential usability to control post-weaning diarrhoea (PWD), which is one of the top indications for antibiotics usage in the pig production. A very cost-efficient and rapid one-step expanded bed adsorption (EBA) chromatography procedure was used to purify pig immunoglobulin G from slaughterhouse pig plasma (more than 100 litres), resulting in >85% pure pig IgG (ppIgG). The ppIgG thus comprised natural pig immunoglobulins and was subsequently shown to contain activity towards four pig-relevant bacterial strains (three different types of Escherichia coli and one type of Salmonella enterica) but not towards a fish pathogen (Yersinia ruckeri), and was demonstrated to inhibit the binding of the four pig relevant bacteria to a pig intestinal cell line (IPEC-J2). Finally it was demonstrated in an in vivo weaning piglet model for intestinal colonization with an E. coli F4+ challenge strain that ppIgG given in the feed significantly reduced shedding of the challenge strain, reduced the proportion of the bacterial family Enterobacteriaceae, increased the proportion of families Enterococcoceae and Streptococcaceae and generally increased ileal microbiota diversity. Conclusively, our data support the idea that natural IgG directly purified from pig plasma and given as a feed supplement can be used in modern swine production as an efficient and cost-effective means for reducing both occurrence of PWD and antibiotics usage and with a potential for the prevention and treatment of other intestinal infectious diseases even if the causative agent might not be known.
Collapse
|
12
|
Burnouf T, Seghatchian J. “Go no Go” in plasma fractionation in the world’s emerging economies: still a question asked 70 years after the COHN process was developed! Transfus Apher Sci 2015; 51:113-9. [PMID: 25457750 PMCID: PMC7106424 DOI: 10.1016/j.transci.2014.10.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In the late 1980s, following the human immunodeficiency virus (HIV) epidemic and transfusion-transmitted infections from plasma-derived coagulation factor concentrates to hemophiliacs, many “advanced thinkers” claimed that plasma-derived products would be completely replaced by the year 2000 by safe recombinant products in most developed countries. However, things have not turned out that way, due to both the continual progress witnessed in plasma fractionation and viral-reduction technologies and technical difficulties still being encountered in developing more cost-effective non-immunogenic, fully active recombinant therapeutic proteins. Accordingly, plasma fractionation remains a reasonably healthy industry worldwide, with an ever-increasing volume of plasma fractionated each year to meet the demands for safe and effective plasma-derived medicines at the global level. While high-income countries currently have generally good access to a panel of plasma-derived and recombinant products, desperate shortages of fractionated plasma products remain in developing economies, and patients still have to be treated inadequately. The steady development of the collection of whole blood in developing economies, to gradually cover the recognized needs for red blood cell concentrates, generates an increasing volume of recovered plasma that is currently wasted. Incentives are therefore high for those countries to consider fractionating such plasma as a means of enhancing their supply of products to treat patients, thereby also decreasing the level of dependence on imported products. Challenges of local plasma fractionation in developing economies are high, in a context where the technological and regulatory sophistication of the plasma fractionation industry is often underestimated, and the blood supply may be exposed to emerging infectious agents. In parallel, plasma product quality requirements and drivers are evolving in developed economies as is the awareness of clinicians to newer uses of products such as intravenous immunoglobulins, somewhat deviating from what currently remain the basic needs of developing countries in terms of affordable safe plasma products. Global market trends for plasma-derived products, through plasma fractionation, are still increasing, despite increasing use of recombinant products, and attention is being focused on the five Ws of the fractionation field: which products; where; when; what and how much; and who will be the main suppliers?
Collapse
Affiliation(s)
- Thierry Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.
| | | |
Collapse
|
13
|
Affiliation(s)
- T. Burnouf
- Graduate Institute of Biomedical Materials and Tissue Engineering; Taipei Medical University; Taipei Taiwan
| |
Collapse
|
14
|
Kelly W, Garcia P, McDermott S, Mullen P, Kamguia G, Jones G, Ubiera A, Göklen K. Experimental characterization of next-generation expanded-bed adsorbents for capture of a recombinant protein expressed in high-cell-density yeast fermentation. Biotechnol Appl Biochem 2013; 60:510-20. [PMID: 23745765 DOI: 10.1002/bab.1133] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Accepted: 05/29/2013] [Indexed: 11/06/2022]
Abstract
Expanded-bed adsorption (EBA) can be particularly useful in protein recovery from high-cell-density fermentation broth where conventional methods for harvest and clarification, such as continuous centrifugation and depth filtration, demand long processing times and are associated with high costs. In this work, the use of next-generation high-particle-density EBA adsorbents, including two mixed-mode resins, for the direct capture of a recombinant protein expressed in yeast at high cell densities is evaluated. Using classical experimental approaches and under different conditions (pH, salt, etc.), Langmuir isotherm parameters for these resins are obtained along with pore diffusivity values. Additional batch adsorption studies with Fastline® MabDirect, the resin that demonstrated the highest static binding capacity for the recombinant protein of interest under the conditions evaluated in this study, indicate competitive binding of nontarget proteins and approximately a 30% reduction in equilibrium binding capacity to 50 mg/mL settled bed in the presence of a 5%-10% cell concentration. Packed-bed (PB) dynamic binding capacities for the MabDirect resin (25-40 mg/mL PB) were significantly higher than for the Fastline® HSA resin and for the MabDirect MM resin in expanded-bed mode (5-10 mg/mL settled bed). Bed expansion behavior for the mMabDirect MM resin along with process yield and eluate purity are identified as a function of linear velocity and cell density, demonstrating process feasibility for pilot scale use.
Collapse
Affiliation(s)
- William Kelly
- College of Engineering, Villanova University, Villanova, PA, USA
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Wu YW, Champagne J, Toueille M, Gantier R, Burnouf T. Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG. Transfusion 2013; 54:169-78. [DOI: 10.1111/trf.12243] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Revised: 03/30/2013] [Accepted: 03/30/2013] [Indexed: 11/28/2022]
Affiliation(s)
- Yu-Wen Wu
- Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine; Taipei Medical University; Taipei Taiwan
- Research and Development, Chromatography Applications; Pall Life Sciences; Cergy France
- Pall Life Sciences; Northborough Massachusetts
- Human Protein Process Sciences (HPPS); Lille France
| | - Jérôme Champagne
- Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine; Taipei Medical University; Taipei Taiwan
- Research and Development, Chromatography Applications; Pall Life Sciences; Cergy France
- Pall Life Sciences; Northborough Massachusetts
- Human Protein Process Sciences (HPPS); Lille France
| | - Magali Toueille
- Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine; Taipei Medical University; Taipei Taiwan
- Research and Development, Chromatography Applications; Pall Life Sciences; Cergy France
- Pall Life Sciences; Northborough Massachusetts
- Human Protein Process Sciences (HPPS); Lille France
| | - René Gantier
- Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine; Taipei Medical University; Taipei Taiwan
- Research and Development, Chromatography Applications; Pall Life Sciences; Cergy France
- Pall Life Sciences; Northborough Massachusetts
- Human Protein Process Sciences (HPPS); Lille France
| | - Thierry Burnouf
- Institute of Medical Biomaterials and Tissue Engineering, College of Oral Medicine; Taipei Medical University; Taipei Taiwan
- Research and Development, Chromatography Applications; Pall Life Sciences; Cergy France
- Pall Life Sciences; Northborough Massachusetts
- Human Protein Process Sciences (HPPS); Lille France
| |
Collapse
|
16
|
Vargas M, Segura A, Herrera M, Villalta M, Angulo Y, Gutiérrez JM, León G, Burnouf T. Purification of IgG and albumin from human plasma by aqueous two phase system fractionation. Biotechnol Prog 2012; 28:1005-11. [PMID: 22619188 DOI: 10.1002/btpr.1565] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Revised: 05/07/2012] [Indexed: 11/05/2022]
Abstract
The current shortages in human plasma products at global levels justify the development of new, cost effective plasma fractionation methods. We have developed a fractionation process to obtain immunoglobulin G (IgG) and albumin-enriched fractions based on polymer-salt aqueous two phase system (ATPS). A small-scale (0.02 L) ATPS composed of polyethyleneglycol 3350 (PEG), potassium phosphate and sodium chloride, at pH 6.1, was evaluated and subjected to 50-fold scale-up (1 L). Further purification of the fractions was performed using caprylic acid precipitation and ion exchange chromatography. Similar yield and purity were obtained at both small and large scales. IgG precipitated in the PEG rich upper phase at 83% recovery and 2.75-fold purification factor. An 81% pure albumin fraction was obtained in the salt rich bottom phase with a 91% yield. After polishing, IgG was obtained at a recovery of 70% and a purity of 92%. Corresponding values for albumin were 91% and 90%. This IgG and albumin fractionation technology deserves further evaluation as it may represent a potential alternative to conventional plasma fractionation methods.
Collapse
Affiliation(s)
- Mariángela Vargas
- Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Technology trends in antibody purification. J Chromatogr A 2012; 1221:57-70. [DOI: 10.1016/j.chroma.2011.10.034] [Citation(s) in RCA: 187] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2011] [Revised: 10/09/2011] [Accepted: 10/12/2011] [Indexed: 01/21/2023]
|
18
|
Purification of coagulation factor VIII using chromatographic methods. Direct chromatography of plasma in anion exchange resins. Biotechnol Lett 2010; 32:1207-14. [DOI: 10.1007/s10529-010-0282-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2010] [Accepted: 04/16/2010] [Indexed: 10/19/2022]
|